Results 161 to 170 of about 21,799 (237)

Knowledge and Attitude of Aseer Region Pharmacists Toward Biosimilar Medicines: A Descriptive Study. [PDF]

Healthcare (Basel)
Alqahtani S, Almanasef M.
europepmc   +1 more source

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study. [PDF]

J Clin Med
Shehab M, Almajdi A, Abdullah I, Alrashed F.   +3 more
europepmc   +1 more source

Biosimilars [PDF]

Pharmazie in unserer Zeit, 2012
openaire   +1 more source

The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings. [PDF]

Health Aff Sch
Beinfeld MT, Ghule P, LaMountain F, Wong W, Ko S, Chambers JD.   +5 more
europepmc   +1 more source

Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]

Pharmaceuticals (Basel)
Ponamarev VS.
europepmc   +1 more source

Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study. [PDF]

Biologics
Pápista M, Resál T, Bacsur P, Kata D, Farkas B, Bálint A, Fábián A, Bor R, Ivány E, Szepes Z, Farkas K, Juhász Z, Buzás N, Molnár T.   +13 more
europepmc   +1 more source

Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. [PDF]

Ther Adv Med Oncol
Qi H, Huang Y, Zhang W, Li J, Wang T, Ying Y, Chen B, Miao F, Li Q.   +8 more
europepmc   +1 more source

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. [PDF]

World J Gastroenterol
Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.   +8 more
europepmc   +1 more source

Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration’ by Marshall et al. [PDF]

, 2016
Emery, P, Ghil, J, Vencovský, J, Won Kang, J   +3 more
core   +1 more source

Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization. [PDF]

Turk J Ophthalmol
Özgür A, Yeşilırmak N, İnan MA, Bağrıaçık EÜ, Özmen MC.   +4 more
europepmc   +1 more source